• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Bio-Link - Product Pipeline Review - H2 2011 Product Image

Bio-Link - Product Pipeline Review - H2 2011

  • Published: November 2011
  • 26 pages
  • Global Markets Direct

Bio-Link – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Bio-Link - Product Pipeline Review - H2 2011” provides data on the Bio-Link’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Bio-Link’s corporate website, SEC filings, investor presentations and featured press releases, both from Bio-Link and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Bio-Link - Brief Bio-Link overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Bio-Link human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product READ MORE >



List of Tables
List of Figures
Bio-Link Snapshot
Bio-Link Overview
Key Information
Key Facts
Bio-Link – Research and Development Overview
Key Therapeutic Areas
Bio-Link – Pipeline Review
Pipeline Products by Stage of Development
Bio-Link – Pipeline Products Glance
Bio-Link–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Bio-Link – Drug Profiles
BACE1 Inhibitors
Product Description
Mechanism of Action
R&D Progress
Dynamin Inhibitors For Cancer
Product Description
Mechanism of Action
R&D Progress
Dynamin Modulators
Product Description
Mechanism of Action
R&D Progress
IRAP Inhibitors
Product Description
Mechanism of Action
R&D Progress
Q8008
Product Description
Mechanism of Action
R&D Progress
Q8009
Product Description
Mechanism of Action
R&D Progress
TGR-212
Product Description
Mechanism of Action
R&D Progress
Bio-Link – Pipeline Analysis
Bio-Link – Pipeline Products by Therapeutic Class
Bio-Link - Pipeline Products By Target
Bio-Link – Pipeline Products by Route of Administration
Bio-Link – Pipeline Products by Molecule Type
Bio-Link – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Bio-Link, Deals Summary
Bio-Link, Pharmaceuticals & Healthcare, Deal Details
Licensing Agreements
Centenary Institute of Cancer Medicine and Cell Biology And Bio-Link Enter Into Licensing Agreement With Becton, Dickinson and Company
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Bio-Link – Pipeline by Therapy Area and Indication, H2 2011
Bio-Link – Pipeline by Stage of Development, H2 2011
Bio-Link - Pipeline By Therapeutic Class, H2 2011
Bio-Link - Pipeline By Target, H2 2011
Bio-Link – Pipeline By Route of Administration, H2 2011
Bio-Link – Pipeline By Molecule Type, H2 2011
Bio-Link, Other Locations
Bio-Link, Deals Summary
Centenary Institute of Cancer Medicine and Cell Biology And Bio-Link Enter Into Licensing Agreement With Becton, Dickinson and Company

List of Figures
Bio-Link – Pipeline by Therapy Area and Indication, H2 2011
Bio-Link – Pipeline by Stage of Development, H2 2011
Bio-Link – Pipeline By Therapeutic Class, H2 2011
Bio-Link - Pipeline By Target, H2 2011
Bio-Link – Pipeline By Molecule Type, H2 2011

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Site License The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.
Enterprisewide The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS